Shenzhen Salubris Pharmaceuticals (XSEC:002294) Stock Valuation, Peer Comparison & Price Targets

Q: What is the Fair Price of 002294 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

002294 (CN¥31.87) is trading below our estimate of [[fair value]] (CN¥46.08)

Share Price vs Fair Value

What is the Fair Price of 002294 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 002294 (CN¥31.87) is trading below our estimate of fair value (CN¥46.08)

Significantly Below Fair Value: 002294 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 002294?

Key metric: As 002294 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 002294. This is calculated by dividing 002294's market cap by their current earnings.
What is 002294's PE Ratio?
PE Ratio	58.2x
Earnings	CN¥610.61m
Market Cap	CN¥35.53b

002294 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	8.6x
Enterprise Value/EBITDA	36x
PEG Ratio	3.8x

Price to Earnings Ratio vs Peers

How does 002294's PE Ratio compare to its peers?

The above table shows the PE ratio for 002294 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	60x
600079 Humanwell Healthcare (Group)Ltd	18.2x	13.7%	CN¥35.6b
300765 CSPC Innovation Pharmaceutical	73.7x	37.5%	CN¥37.8b
000423 Dong-E-E-JiaoLtd	23.9x	13.9%	CN¥36.4b
600518 Kangmei Pharmaceutical	124.2x	n/a	CN¥31.7b
002294 Shenzhen Salubris Pharmaceuticals	58.2x	15.5%	CN¥35.5b

Price-To-Earnings vs Peers: 002294 is good value based on its Price-To-Earnings Ratio (58.2x) compared to the peer average (60x).

Price to Earnings Ratio vs Industry

How does 002294's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 002294 is expensive based on its Price-To-Earnings Ratio (58.2x) compared to the CN Pharmaceuticals industry average (29.6x).

Price to Earnings Ratio vs Fair Ratio

What is 002294's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

002294 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	58.2x
Fair PE Ratio	28x

Price-To-Earnings vs Fair Ratio: 002294 is expensive based on its Price-To-Earnings Ratio (58.2x) compared to the estimated Fair Price-To-Earnings Ratio (28x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 002294 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	CN¥31.87	CN¥37.00 +16.1%	13.5%	CN¥42.00	CN¥32.00	n/a	2
Nov ’25	CN¥32.80	CN¥37.00 +12.8%	13.5%	CN¥42.00	CN¥32.00	n/a	2
Oct ’25	CN¥34.66	CN¥37.50 +8.2%	12.0%	CN¥42.00	CN¥33.00	n/a	2
Sep ’25	CN¥30.15	CN¥37.50 +24.4%	12.0%	CN¥42.00	CN¥33.00	n/a	2
Aug ’25	CN¥28.85	CN¥37.00 +28.2%	10.8%	CN¥41.00	CN¥33.00	n/a	2
Jul ’25	CN¥27.13	CN¥37.00 +36.4%	10.8%	CN¥41.00	CN¥33.00	n/a	2
Jun ’25	CN¥27.33	CN¥37.00 +35.4%	10.8%	CN¥41.00	CN¥33.00	n/a	2
May ’25	CN¥31.92	CN¥37.00 +15.9%	10.8%	CN¥41.00	CN¥33.00	n/a	2
Apr ’25	CN¥29.50	CN¥37.00 +25.4%	10.8%	CN¥41.00	CN¥33.00	n/a	2
Mar ’25	CN¥28.83	CN¥37.00 +28.3%	10.8%	CN¥41.00	CN¥33.00	n/a	2
Feb ’25	CN¥25.91	CN¥37.00 +42.8%	10.8%	CN¥41.00	CN¥33.00	n/a	2
Jan ’25	CN¥32.66	CN¥37.00 +13.3%	10.8%	CN¥41.00	CN¥33.00	n/a	2
Dec ’24	CN¥33.11	CN¥37.00 +11.7%	10.8%	CN¥41.00	CN¥33.00	n/a	2
Nov ’24	CN¥31.94	CN¥34.98 +9.5%	12.4%	CN¥41.00	CN¥31.00	CN¥32.80	3
Oct ’24	CN¥29.65	CN¥31.98 +7.8%	3.0%	CN¥32.95	CN¥31.00	CN¥34.66	2
Sep ’24	CN¥27.51	CN¥34.05 +23.8%	0.1%	CN¥34.10	CN¥34.00	CN¥30.15	2
Aug ’24	CN¥31.85	CN¥34.05 +6.9%	0.1%	CN¥34.10	CN¥34.00	CN¥28.85	2
Jul ’24	CN¥31.19	CN¥33.80 +8.4%	0.9%	CN¥34.10	CN¥33.50	CN¥27.13	2
Jun ’24	CN¥35.04	CN¥33.80 -3.5%	0.9%	CN¥34.10	CN¥33.50	CN¥27.33	2
May ’24	CN¥35.93	CN¥33.80 -5.9%	0.9%	CN¥34.10	CN¥33.50	CN¥31.92	2
Apr ’24	CN¥35.36	CN¥34.05 -3.7%	1.6%	CN¥34.60	CN¥33.50	CN¥29.50	2
Mar ’24	CN¥35.87	CN¥34.05 -5.1%	1.6%	CN¥34.60	CN¥33.50	CN¥28.83	2
Feb ’24	CN¥36.09	CN¥30.65 -15.1%	12.9%	CN¥34.60	CN¥26.70	CN¥25.91	2
Jan ’24	CN¥32.85	CN¥25.35 -22.8%	5.3%	CN¥26.70	CN¥24.00	CN¥32.66	2
Dec ’23	CN¥34.22	CN¥25.35 -25.9%	5.3%	CN¥26.70	CN¥24.00	CN¥33.11	2
Nov ’23	CN¥31.56	CN¥25.35 -19.7%	5.3%	CN¥26.70	CN¥24.00	CN¥31.94	2

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥48.4b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥30.51

7D

2.2%

1Y

7.6%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.59

7D

-2.4%

1Y

12.8%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.91

7D

-1.8%

1Y

14.6%

Shenzhen Salubris Pharmaceuticals Valuation